195 related articles for article (PubMed ID: 23680921)
1. Assessment of the absorption, metabolism and excretion of [¹⁴C]pasireotide in healthy volunteers using accelerator mass spectrometry.
Lin TH; Hu K; Flarakos J; Sharr-McMahon M; Mangold JB; He H; Wang Y
Cancer Chemother Pharmacol; 2013 Jul; 72(1):181-8. PubMed ID: 23680921
[TBL] [Abstract][Full Text] [Related]
2. Tolerability and dose proportional pharmacokinetics of pasireotide administered as a single dose or two divided doses in healthy male volunteers: a single-center, open-label, ascending-dose study.
Petersenn S; Hu K; Maldonado M; Zhang Y; Lasher J; Bouillaud E; Wang Y; Mann K; Unger N
Clin Ther; 2012 Mar; 34(3):677-88. PubMed ID: 22364824
[TBL] [Abstract][Full Text] [Related]
3. Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers.
Petersenn S; Unger N; Hu K; Weisshaar B; Zhang Y; Bouillaud E; Reséndiz KH; Wang Y; Mann K
J Clin Pharmacol; 2012 Jul; 52(7):1017-27. PubMed ID: 21673137
[TBL] [Abstract][Full Text] [Related]
4. Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers.
Zollinger M; Lozac'h F; Hurh E; Emotte C; Bauly H; Swart P
Cancer Chemother Pharmacol; 2014 Jul; 74(1):63-75. PubMed ID: 24817600
[TBL] [Abstract][Full Text] [Related]
5. Absorption, distribution, metabolism, and excretion of [(14)C]BYL719 (alpelisib) in healthy male volunteers.
James A; Blumenstein L; Glaenzel U; Jin Y; Demailly A; Jakab A; Hansen R; Hazell K; Mehta A; Trandafir L; Swart P
Cancer Chemother Pharmacol; 2015 Oct; 76(4):751-60. PubMed ID: 26254025
[TBL] [Abstract][Full Text] [Related]
6. Effect of hepatic impairment on the pharmacokinetics of pasireotide (SOM230): results from a multicenter phase I study.
Horsmans Y; Hu K; Ruffin M; Wang Y; Song D; Bouillaud E; Wang Y; Mazur D; Botha FP; Heuman DM
J Clin Pharmacol; 2012 Apr; 52(4):552-8. PubMed ID: 22282526
[TBL] [Abstract][Full Text] [Related]
7. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
[TBL] [Abstract][Full Text] [Related]
8. Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study.
Beglinger C; Hu K; Wang Y; Bouillaud E; Darstein C; Wang Y; Mohideen P
Endocrine; 2012 Oct; 42(2):366-74. PubMed ID: 22527887
[TBL] [Abstract][Full Text] [Related]
9. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
[TBL] [Abstract][Full Text] [Related]
10. A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry.
Graham RA; Lum BL; Morrison G; Chang I; Jorga K; Dean B; Shin YG; Yue Q; Mulder T; Malhi V; Xie M; Low JA; Hop CE
Drug Metab Dispos; 2011 Aug; 39(8):1460-7. PubMed ID: 21602311
[TBL] [Abstract][Full Text] [Related]
11. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers.
Waldmeier F; Glaenzel U; Wirz B; Oberer L; Schmid D; Seiberling M; Valencia J; Riviere GJ; End P; Vaidyanathan S
Drug Metab Dispos; 2007 Aug; 35(8):1418-28. PubMed ID: 17510248
[TBL] [Abstract][Full Text] [Related]
12. A phase I, open-label, mass balance study of [(14)C] dacomitinib (PF-00299804) in healthy male volunteers.
Bello CL; Smith E; Ruiz-Garcia A; Ni G; Alvey C; Loi CM
Cancer Chemother Pharmacol; 2013 Aug; 72(2):379-85. PubMed ID: 23760812
[TBL] [Abstract][Full Text] [Related]
13. Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humans.
Karanam B; Madeira M; Bradley S; Wenning L; Desai R; Soli E; Schenk D; Jones A; Dean B; Doss G; Garrett G; Crumley T; Nirula A; Lai E
Drug Metab Dispos; 2007 Jul; 35(7):1196-202. PubMed ID: 17431030
[TBL] [Abstract][Full Text] [Related]
14. Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors.
Dubbelman AC; Rosing H; Jansen RS; Mergui-Roelvink M; Huitema AD; Koetz B; Lymboura M; Reyderman L; Lopez-Anaya A; Schellens JH; Beijnen JH
Drug Metab Dispos; 2012 Feb; 40(2):313-21. PubMed ID: 22041109
[TBL] [Abstract][Full Text] [Related]
15. Effects of somatostatin analogs on glucose homeostasis in rats.
Schmid HA; Brueggen J
J Endocrinol; 2012 Jan; 212(1):49-60. PubMed ID: 21987782
[TBL] [Abstract][Full Text] [Related]
16. A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers.
Golor G; Hu K; Ruffin M; Buchelt A; Bouillaud E; Wang Y; Maldonado M
Drug Des Devel Ther; 2012; 6():71-9. PubMed ID: 22573933
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects.
Chen N; Wen L; Lau H; Surapaneni S; Kumar G
Cancer Chemother Pharmacol; 2012 Mar; 69(3):789-97. PubMed ID: 22037879
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects.
Darwish M; Nunez R; Youakim JM; Robertson P
Clin Drug Investig; 2024 Jan; 44(1):21-33. PubMed ID: 38017349
[TBL] [Abstract][Full Text] [Related]
19. Effect of verapamil on the pharmacokinetics of pasireotide in healthy volunteers.
Kornberger R; Ting LS; Tripathi AP; Rodrigues H; Nesheiwat D; Passos VQ; Hu K
J Clin Pharmacol; 2014 Nov; 54(11):1263-71. PubMed ID: 24788408
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: a phase I, single-center, open-label, randomized study.
Chen X; Shen G; Jiang J; Liu H; Hu K; Darstein C; Lasher J; Hu P
Clin Ther; 2014 Aug; 36(8):1196-210. PubMed ID: 25012727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
